Flindr Therapeutics

Flindr Therapeutics is a precision oncology therapeutics company developing first-in-class, small molecule inhibitors for cancer treatment. Their lead asset targets the RNF31 protein, and they utilize the "ImmunoGram Drug Discovery Engine" to identify and develop these inhibitors. The company focuses on translating precision targets into precision therapies to improve patient outcomes.

Funding Round: Series A

Funding Amount: €20M

Date: 24-Apr-2024

Investors: V-Bio Ventures, Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital, Oncode Oncology Bridge Fund, Swanbridge, Brabantse Ontwikkelings Maatschappij (BOM)

Markets: Oncology, Biotechnology, Pharmaceuticals

HQ: Oss, North Brabant, Netherlands

Founded: 2020

Website: https://flindrtx.com/

LinkedIn: https://www.linkedin.com/company/flindr-therapeutics/

Twitter: https://twitter.com/FlindrT240408

Instagram:

Facebook:

Crunchbase: https://www.crunchbase.com/organization/immagene

Pitchbook: https://pitchbook.com/profiles/company/443258-29